Emerging therapies: ESPRIT.
Moussouttas
Michael
M
D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D002545:Brain Ischemia / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D002543:Cerebral Hemorrhage / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control; D002986:Clinical Trials as Topic / Q000592:standards / Q000706:statistics & numerical data; D004176:Dipyridamole / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D006801:Humans; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D015203:Reproducibility of Results; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control
D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D001241:Aspirin